What is Progyny, Inc. (PGNY)?

Progyny, Inc. (PGNY) is a stock in the Healthcare sector, Medical - Healthcare Plans industry. View full analysis on Stocks360.

What is the current price of PGNY?

The current price of PGNY is $28.40. Prices are updated in real time on Stocks360.

What is PGNY's price-to-earnings (PE) ratio?

PGNY's trailing twelve-month PE ratio is 29.28, based on current price and earnings per share data available on Stocks360.

What is PGNY's market capitalization?

PGNY's market capitalization is $2,179,041,120.00, placing it in the mid-cap tier.

Progyny, Inc. (PGNY)

Stock analysis · NASDAQ · Healthcare · Medical - Healthcare Plans

$28.40

Market Cap

$2.18B

PE (TTM)

29.28

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.02

Day Range

$28.03 – $28.58

52-wk Range

$16.10 – $33.07

Avg Volume

N/A

Volume

657.46K

Progyny, Inc. (PGNY) is a publicly traded company in the Healthcare sector. Latest price: $28.40. Market cap $2.18B. Trailing PE 29.28. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $18.65 2026-10-29 · $28.40 (+52.28%)

Earnings

Most Recent

Aug 6, 2026

EPS $0.36 vs est. $0.33

Beat by $0.03

Next Earnings

Nov 4, 2026

EPS estimate $0.31

Proprietary Signals

Signal snapshot temporarily unavailable.

About Progyny, Inc.

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	29.28×
P/S (TTM)	1.66×
P/B	4.90×
PEG	0.52×
P/FCF (TTM)	10.00×
EV / EBITDA	16.16×
EV / Sales	1.57×
Earnings Yield	3.54%
Free Cash Flow Yield	10.00%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.05B
Revenue (TTM)	$1.31B
Net Income (TTM)	$77.19M
Free Cash Flow (TTM)	$217.99M
Net Debt	-$125.66M
Working Capital	$272.93M
Gross Margin	24.57%
Operating Margin	8.55%
Net Margin	6.00%
Return on Equity	15.98%
Return on Invested Capital	15.32%

Peers